ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Innovative Drug CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-33X16962
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Innovative Drug CDMO Market Research Report 2024
BUY CHAPTERS

Global Innovative Drug CDMO Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-33X16962
Report
November 2025
Pages:124
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Skyepharma
Asymchem
Recipharm
CoreRx Inc.
Axplora
KINDEVA
Quotient Sciences
Lonza
CentreOne

Innovative Drug CDMO Market

The global Innovative Drug CDMO market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
From a downstream perspective, Pharmaceutical and Biotechnology Companies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Innovative Drug CDMO leading manufacturers including Skyepharma, Asymchem, Recipharm, CoreRx, Pierre Fabre, CentreOne, Axplora, Kindeva, Quotient Sciences, Lonza, etc., dominate supply; the top five capture approximately % of global revenue, with Skyepharma leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Innovative Drug CDMO market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Innovative Drug CDMO Market Report

Report Metric Details
Report Name Innovative Drug CDMO Market
Segment by Type
  • Small Molecule CDMO
  • Macromolecule CDMO
  • Cell Gene Therapy (CGT) CDMO
Segment by Application
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutions
  • Hospital
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Skyepharma, Asymchem, Recipharm, CoreRx, Pierre Fabre, CentreOne, Axplora, Kindeva, Quotient Sciences, Lonza
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Innovative Drug CDMO study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
  • Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 14: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Innovative Drug CDMO Market report?

Ans: The main players in the Innovative Drug CDMO Market are Skyepharma, Asymchem, Recipharm, CoreRx, Pierre Fabre, CentreOne, Axplora, Kindeva, Quotient Sciences, Lonza

What are the Application segmentation covered in the Innovative Drug CDMO Market report?

Ans: The Applications covered in the Innovative Drug CDMO Market report are Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Hospital, Others

What are the Type segmentation covered in the Innovative Drug CDMO Market report?

Ans: The Types covered in the Innovative Drug CDMO Market report are Small Molecule CDMO, Macromolecule CDMO, Cell Gene Therapy (CGT) CDMO

1 Study Coverage
1.1 Introduction to Innovative Drug CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Innovative Drug CDMO Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Small Molecule CDMO
1.2.3 Macromolecule CDMO
1.2.4 Cell Gene Therapy (CGT) CDMO
1.3 Market Segmentation by Application
1.3.1 Global Innovative Drug CDMO Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research and Academic Institutions
1.3.4 Hospital
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Innovative Drug CDMO Revenue Estimates and Forecasts 2020-2031
2.2 Global Innovative Drug CDMO Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Innovative Drug CDMO Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Innovative Drug CDMO Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Small Molecule CDMO Market Size by Players
3.3.2 Macromolecule CDMO Market Size by Players
3.3.3 Cell Gene Therapy (CGT) CDMO Market Size by Players
3.4 Global Innovative Drug CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Innovative Drug CDMO Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Innovative Drug CDMO Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Innovative Drug CDMO Market Size by Type (2020-2031)
6.4 North America Innovative Drug CDMO Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Innovative Drug CDMO Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Innovative Drug CDMO Market Size by Type (2020-2031)
7.4 Europe Innovative Drug CDMO Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Innovative Drug CDMO Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Innovative Drug CDMO Market Size by Type (2020-2031)
8.4 Asia-Pacific Innovative Drug CDMO Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Innovative Drug CDMO Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Innovative Drug CDMO Market Size by Type (2020-2031)
9.4 Central and South America Innovative Drug CDMO Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Innovative Drug CDMO Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Innovative Drug CDMO Market Size by Type (2020-2031)
10.4 Middle East and Africa Innovative Drug CDMO Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Innovative Drug CDMO Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Skyepharma
11.1.1 Skyepharma Corporation Information
11.1.2 Skyepharma Business Overview
11.1.3 Skyepharma Innovative Drug CDMO Product Features and Attributes
11.1.4 Skyepharma Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.1.5 Skyepharma Innovative Drug CDMO Revenue by Product in 2024
11.1.6 Skyepharma Innovative Drug CDMO Revenue by Application in 2024
11.1.7 Skyepharma Innovative Drug CDMO Revenue by Geographic Area in 2024
11.1.8 Skyepharma Innovative Drug CDMO SWOT Analysis
11.1.9 Skyepharma Recent Developments
11.2 Asymchem
11.2.1 Asymchem Corporation Information
11.2.2 Asymchem Business Overview
11.2.3 Asymchem Innovative Drug CDMO Product Features and Attributes
11.2.4 Asymchem Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.2.5 Asymchem Innovative Drug CDMO Revenue by Product in 2024
11.2.6 Asymchem Innovative Drug CDMO Revenue by Application in 2024
11.2.7 Asymchem Innovative Drug CDMO Revenue by Geographic Area in 2024
11.2.8 Asymchem Innovative Drug CDMO SWOT Analysis
11.2.9 Asymchem Recent Developments
11.3 Recipharm
11.3.1 Recipharm Corporation Information
11.3.2 Recipharm Business Overview
11.3.3 Recipharm Innovative Drug CDMO Product Features and Attributes
11.3.4 Recipharm Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.3.5 Recipharm Innovative Drug CDMO Revenue by Product in 2024
11.3.6 Recipharm Innovative Drug CDMO Revenue by Application in 2024
11.3.7 Recipharm Innovative Drug CDMO Revenue by Geographic Area in 2024
11.3.8 Recipharm Innovative Drug CDMO SWOT Analysis
11.3.9 Recipharm Recent Developments
11.4 CoreRx
11.4.1 CoreRx Corporation Information
11.4.2 CoreRx Business Overview
11.4.3 CoreRx Innovative Drug CDMO Product Features and Attributes
11.4.4 CoreRx Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.4.5 CoreRx Innovative Drug CDMO Revenue by Product in 2024
11.4.6 CoreRx Innovative Drug CDMO Revenue by Application in 2024
11.4.7 CoreRx Innovative Drug CDMO Revenue by Geographic Area in 2024
11.4.8 CoreRx Innovative Drug CDMO SWOT Analysis
11.4.9 CoreRx Recent Developments
11.5 Pierre Fabre
11.5.1 Pierre Fabre Corporation Information
11.5.2 Pierre Fabre Business Overview
11.5.3 Pierre Fabre Innovative Drug CDMO Product Features and Attributes
11.5.4 Pierre Fabre Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.5.5 Pierre Fabre Innovative Drug CDMO Revenue by Product in 2024
11.5.6 Pierre Fabre Innovative Drug CDMO Revenue by Application in 2024
11.5.7 Pierre Fabre Innovative Drug CDMO Revenue by Geographic Area in 2024
11.5.8 Pierre Fabre Innovative Drug CDMO SWOT Analysis
11.5.9 Pierre Fabre Recent Developments
11.6 CentreOne
11.6.1 CentreOne Corporation Information
11.6.2 CentreOne Business Overview
11.6.3 CentreOne Innovative Drug CDMO Product Features and Attributes
11.6.4 CentreOne Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.6.5 CentreOne Recent Developments
11.7 Axplora
11.7.1 Axplora Corporation Information
11.7.2 Axplora Business Overview
11.7.3 Axplora Innovative Drug CDMO Product Features and Attributes
11.7.4 Axplora Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.7.5 Axplora Recent Developments
11.8 Kindeva
11.8.1 Kindeva Corporation Information
11.8.2 Kindeva Business Overview
11.8.3 Kindeva Innovative Drug CDMO Product Features and Attributes
11.8.4 Kindeva Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.8.5 Kindeva Recent Developments
11.9 Quotient Sciences
11.9.1 Quotient Sciences Corporation Information
11.9.2 Quotient Sciences Business Overview
11.9.3 Quotient Sciences Innovative Drug CDMO Product Features and Attributes
11.9.4 Quotient Sciences Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.9.5 Quotient Sciences Recent Developments
11.10 Lonza
11.10.1 Lonza Corporation Information
11.10.2 Lonza Business Overview
11.10.3 Lonza Innovative Drug CDMO Product Features and Attributes
11.10.4 Lonza Innovative Drug CDMO Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Innovative Drug CDMOIndustry Chain Analysis
12.1 Innovative Drug CDMO Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Innovative Drug CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Innovative Drug CDMO Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Skyepharma
Asymchem
Recipharm
CoreRx Inc.
Axplora
KINDEVA
Quotient Sciences
Lonza
CentreOne
List of Tables
 Table 1. Global Innovative Drug CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Innovative Drug CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Innovative Drug CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Innovative Drug CDMO Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Innovative Drug CDMO Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 7. Global Innovative Drug CDMO Revenue by Players (2020-2025) & (US$ Million)
 Table 8. Global Innovative Drug CDMO Revenue Market Share by Players (2020-2025)
 Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 10. Global Innovative Drug CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Innovative Drug CDMO as of 2024)
 Table 11. Global Innovative Drug CDMO Average Gross Margin (%) by Player (2020 VS 2024)
 Table 12. Global Innovative Drug CDMO Companies Headquarters
 Table 13. Global Innovative Drug CDMO Market Concentration Ratio (CR5 and HHI)
 Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 16. Global Innovative Drug CDMO Revenue by Type (2020-2025) & (US$ Million)
 Table 17. Global Innovative Drug CDMO Revenue by Type (2026-2031) & (US$ Million)
 Table 18. Key Product Attributes and Differentiation
 Table 19. Global Innovative Drug CDMO Revenue by Application (2020-2025) & (US$ Million)
 Table 20. Global Innovative Drug CDMO Revenue by Application (2026-2031) & (US$ Million)
 Table 21. Innovative Drug CDMO High-Growth Sectors Demand CAGR (2024-2031)
 Table 22. Top Customers by Region
 Table 23. Top Customers by Application
 Table 24. North America Innovative Drug CDMO Growth Accelerators and Market Barriers
 Table 25. North America Innovative Drug CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 26. Europe Innovative Drug CDMO Growth Accelerators and Market Barriers
 Table 27. Europe Innovative Drug CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 28. Asia-Pacific Innovative Drug CDMO Growth Accelerators and Market Barriers
 Table 29. Asia-Pacific Innovative Drug CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 30. Central and South America Innovative Drug CDMO Investment Opportunities and Key Challenges
 Table 31. Central and South America Innovative Drug CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 32. Middle East and Africa Innovative Drug CDMO Investment Opportunities and Key Challenges
 Table 33. Middle East and Africa Innovative Drug CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 34. Skyepharma Corporation Information
 Table 35. Skyepharma Description and Major Businesses
 Table 36. Skyepharma Product Features and Attributes
 Table 37. Skyepharma Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 38. Skyepharma Revenue Proportion by Product in 2024
 Table 39. Skyepharma Revenue Proportion by Application in 2024
 Table 40. Skyepharma Revenue Proportion by Geographic Area in 2024
 Table 41. Skyepharma Innovative Drug CDMO SWOT Analysis
 Table 42. Skyepharma Recent Developments
 Table 43. Asymchem Corporation Information
 Table 44. Asymchem Description and Major Businesses
 Table 45. Asymchem Product Features and Attributes
 Table 46. Asymchem Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 47. Asymchem Revenue Proportion by Product in 2024
 Table 48. Asymchem Revenue Proportion by Application in 2024
 Table 49. Asymchem Revenue Proportion by Geographic Area in 2024
 Table 50. Asymchem Innovative Drug CDMO SWOT Analysis
 Table 51. Asymchem Recent Developments
 Table 52. Recipharm Corporation Information
 Table 53. Recipharm Description and Major Businesses
 Table 54. Recipharm Product Features and Attributes
 Table 55. Recipharm Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 56. Recipharm Revenue Proportion by Product in 2024
 Table 57. Recipharm Revenue Proportion by Application in 2024
 Table 58. Recipharm Revenue Proportion by Geographic Area in 2024
 Table 59. Recipharm Innovative Drug CDMO SWOT Analysis
 Table 60. Recipharm Recent Developments
 Table 61. CoreRx Corporation Information
 Table 62. CoreRx Description and Major Businesses
 Table 63. CoreRx Product Features and Attributes
 Table 64. CoreRx Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 65. CoreRx Revenue Proportion by Product in 2024
 Table 66. CoreRx Revenue Proportion by Application in 2024
 Table 67. CoreRx Revenue Proportion by Geographic Area in 2024
 Table 68. CoreRx Innovative Drug CDMO SWOT Analysis
 Table 69. CoreRx Recent Developments
 Table 70. Pierre Fabre Corporation Information
 Table 71. Pierre Fabre Description and Major Businesses
 Table 72. Pierre Fabre Product Features and Attributes
 Table 73. Pierre Fabre Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 74. Pierre Fabre Revenue Proportion by Product in 2024
 Table 75. Pierre Fabre Revenue Proportion by Application in 2024
 Table 76. Pierre Fabre Revenue Proportion by Geographic Area in 2024
 Table 77. Pierre Fabre Innovative Drug CDMO SWOT Analysis
 Table 78. Pierre Fabre Recent Developments
 Table 79. CentreOne Corporation Information
 Table 80. CentreOne Description and Major Businesses
 Table 81. CentreOne Product Features and Attributes
 Table 82. CentreOne Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 83. CentreOne Recent Developments
 Table 84. Axplora Corporation Information
 Table 85. Axplora Description and Major Businesses
 Table 86. Axplora Product Features and Attributes
 Table 87. Axplora Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 88. Axplora Recent Developments
 Table 89. Kindeva Corporation Information
 Table 90. Kindeva Description and Major Businesses
 Table 91. Kindeva Product Features and Attributes
 Table 92. Kindeva Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 93. Kindeva Recent Developments
 Table 94. Quotient Sciences Corporation Information
 Table 95. Quotient Sciences Description and Major Businesses
 Table 96. Quotient Sciences Product Features and Attributes
 Table 97. Quotient Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 98. Quotient Sciences Recent Developments
 Table 99. Lonza Corporation Information
 Table 100. Lonza Description and Major Businesses
 Table 101. Lonza Product Features and Attributes
 Table 102. Lonza Revenue (US$ Million) and Gross Margin (2020-2025)
 Table 103. Lonza Recent Developments
 Table 104. Raw Materials Key Suppliers
 Table 105. Distributors List
 Table 106. Market Trends and Market Evolution
 Table 107. Market Drivers and Opportunities
 Table 108. Market Challenges, Risks, and Restraints
 Table 109. Research Programs/Design for This Report
 Table 110. Key Data Information from Secondary Sources
 Table 111. Key Data Information from Primary Sources


List of Figures
 Figure 1. Innovative Drug CDMO Product Picture
 Figure 2. Global Innovative Drug CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Small Molecule CDMO Product Picture
 Figure 4. Macromolecule CDMO Product Picture
 Figure 5. Cell Gene Therapy (CGT) CDMO Product Picture
 Figure 6. Global Innovative Drug CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Pharmaceutical and Biotechnology Companies
 Figure 8. Research and Academic Institutions
 Figure 9. Hospital
 Figure 10. Others
 Figure 11. Innovative Drug CDMO Report Years Considered
 Figure 12. Global Innovative Drug CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 14. Global Innovative Drug CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 15. Global Innovative Drug CDMO Revenue Market Share by Region (2020-2031)
 Figure 16. Global Innovative Drug CDMO Revenue Market Share Ranking (2024)
 Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 18. Small Molecule CDMO Revenue Market Share by Player in 2024
 Figure 19. Macromolecule CDMO Revenue Market Share by Player in 2024
 Figure 20. Cell Gene Therapy (CGT) CDMO Revenue Market Share by Player in 2024
 Figure 21. Global Innovative Drug CDMO Revenue Market Share by Type (2020-2031)
 Figure 22. Global Innovative Drug CDMO Revenue Market Share by Application (2020-2031)
 Figure 23. North America Innovative Drug CDMO Revenue YoY (2020-2031) & (US$ Million)
 Figure 24. North America Top 5 Players Innovative Drug CDMO Revenue (US$ Million) in 2024
 Figure 25. North America Innovative Drug CDMO Revenue (US$ Million) by Type (2020 - 2031)
 Figure 26. North America Innovative Drug CDMO Revenue (US$ Million) by Application (2020-2031)
 Figure 27. US Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 28. Canada Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 29. Mexico Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 30. Europe Innovative Drug CDMO Revenue YoY (2020-2031) & (US$ Million)
 Figure 31. Europe Top 5 Players Innovative Drug CDMO Revenue (US$ Million) in 2024
 Figure 32. Europe Innovative Drug CDMO Revenue (US$ Million) by Type (2020-2031)
 Figure 33. Europe Innovative Drug CDMO Revenue (US$ Million) by Application (2020-2031)
 Figure 34. Germany Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 35. France Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 36. U.K. Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 37. Italy Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 38. Russia Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 39. Asia-Pacific Innovative Drug CDMO Revenue YoY (2020-2031) & (US$ Million)
 Figure 40. Asia-Pacific Top 8 Players Innovative Drug CDMO Revenue (US$ Million) in 2024
 Figure 41. Asia-Pacific Innovative Drug CDMO Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Asia-Pacific Innovative Drug CDMO Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Indonesia Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 44. Japan Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 45. South Korea Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 46. Australia Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 47. India Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 48. Indonesia Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 49. Vietnam Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 50. Malaysia Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 51. Philippines Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 52. Singapore Innovative Drug CDMO Revenue (2020-2031) & (US$ Million)
 Figure 53. Central and South America Innovative Drug CDMO Revenue YoY (2020-2031) & (US$ Million)
 Figure 54. Central and South America Top 5 Players Innovative Drug CDMO Revenue (US$ Million) in 2024
 Figure 55. Central and South America Innovative Drug CDMO Revenue (US$ Million) by Type (2020-2031)
 Figure 56. Central and South America Innovative Drug CDMO Revenue (US$ Million) by Application (2020-2031)
 Figure 57. Brazil Innovative Drug CDMO Revenue (2020-2025) & (US$ Million)
 Figure 58. Argentina Innovative Drug CDMO Revenue (2020-2025) & (US$ Million)
 Figure 59. Middle East and Africa Innovative Drug CDMO Revenue YoY (2020-2031) & (US$ Million)
 Figure 60. Middle East and Africa Top 5 Players Innovative Drug CDMO Revenue (US$ Million) in 2024
 Figure 61. South America Innovative Drug CDMO Revenue (US$ Million) by Type (2020-2031)
 Figure 62. Middle East and Africa Innovative Drug CDMO Revenue (US$ Million) by Application (2020-2031)
 Figure 63. GCC Countries Innovative Drug CDMO Revenue (2020-2025) & (US$ Million)
 Figure 64. Israel Innovative Drug CDMO Revenue (2020-2025) & (US$ Million)
 Figure 65. Egypt Innovative Drug CDMO Revenue (2020-2025) & (US$ Million)
 Figure 66. South Africa Innovative Drug CDMO Revenue (2020-2025) & (US$ Million)
 Figure 67. Innovative Drug CDMO Industry Chain Mapping
 Figure 68. Channels of Distribution (Direct Vs Distribution)
 Figure 69. Bottom-up and Top-down Approaches for This Report
 Figure 70. Data Triangulation
 Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global Small Molecule Innovator CDMO Market Research Report 2025
Global Pharmaceutical Intermediate CDMO Market Research Report 2024
Global Cell Therapy CDMO Market Research Report 2025
Global Chemical API CDMO Market Research Report 2024
Global Cell and Gene Therapy CDMO Market Research Report 2024
Global Exosome CDMO Market Research Report 2024
Intermediate CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Mammalian CDMO Service Market Research Report 2024
Small Molecule CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global CMO and CDMO biotechnology Market Research Report 2024
Global Gene Cell Therapy CDMO Market Research Report 2024
Medical Device CDMO Services Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmaceutical CDMO Pharmaceutical Contract Development and Manufacturing Organization Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Plasmid CDMO Services Market Research Report 2025
Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025
Global Medical Device CDMO and CRO Market Research Report 2025
Softgel CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Active Pharmaceutical Ingredients CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Microbial CDMO Service Market Research Report 2024
Global Antibody and Recombinant Protein CDMO Market Research Report 2025

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-10T20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-6Q20319
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35Z19949
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26E19785
Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions